Enzalutamide, the first-line PCa drug, and palbociclib, the selective CDK4/6 inhibitor in the market, were selected as the positive controls since CDK4/6 are down-regulated in DU145 cells when treated by YK-2-69. This evidence concerns the gene CDK4 and posterior cortical atrophy.